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ABSTRACT 
Immunotherapy as a form of cancer treatment has become increasingly popular in the past 
few decades. Researchers have worked to figure out how to best use the body’s natural 
defense mechanism, the immune system, to fight off and destroy cancer cells. In particular, 
the goal has been to manipulate checkpoint blockades such as CTLA-4 and PD-1 in order 
to take the breaks off of the immune system, allowing for a prolonged immune response 
to the cancer. This work has led to the development of human versions of anti-CTLA4 
antibodies (ipilimumab, tremelimumab) and anti-PD1 antibodies (pembrolizumab and 
Nivolumab) that are currently either FDA approved or being used in clinical trials. Despite 
this progress, the true mechanism of action of these therapeutics is not fully understood. 
To begin to gain an idea of how the treatments worked and differed from one another, an 
immunological snapshot of the immune cell populations in mice under various conditions 
was analyzed and compared. Comparisons were done between mice of different strains 
(BALB/cJ and BL/6), mice of different ages (6-8 weeks and 8-12 months), naïve mice and 
tumor-bearing mice, mice with early tumors and mice with late tumors, as well as 
untreated and treated (anti-CTLA4 or anti-PD1) mice. Results from these sets of 
experiments showed that there are significant variations in regards to some immune cells 
between mice of different groups, which may have an impact on how the immune system 
functions and how effectively tumor regression occurs. These mice models serve as the 
basis for understanding how anti-CTLA4 and anti-PD1 therapeutics affect various immune 
cell populations and will help guide further research in this area.  
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INTRODUCTION 
HISTORY OF CANCER IMMUNOLOGY  
     For years, the most prominent forms of cancer treatment were surgery, chemotherapy, 
and radiation. However, research and scientific advancements over the past few decades 
have brought to the forefront a new and potentially more effective and safer form of 
treatment: immunotherapy. As the link between the immune system and tumors has 
become better understood, it is now clear that manipulation of the body’s natural defense 
mechanisms is likely central in generating long term antitumor therapeutic outcomes (1).  
     Early work showed that mice that were successfully implanted with tumors and that 
recovered could resist re-inoculation with the same tumor line (2). Clowes and Baeslack 
(2) showed that only mice that had shown little to no sign of regression after the first 
inoculation were susceptible to subsequent inoculations of the same tumor.  In 1943, Dr. 
Ludwik Gross (3) demonstrated that immunity against the tumor was not caused by genetic 
differences by immunizing mice against a tumor that originated from an animal in the same 
line (i.e. genetically identical or syngeneic). Gross showed that of 115 inoculated mice, 21 
showed spontaneous regression and that of those 21, most were resistant to re-
inoculation (3). Therefore, Gross was able to show that the immunity was tumor-specific 
and not dependent on genetic differences between the tumor challenged animal and the 
animal from which the tumor was derived.   
     Despite these findings, at the time of Gross’s publication, little else was known about 
the mechanisms of cancer immunology. It was widely believed that cancer cells simply 
overexpressed normal cellular antigens, which the immune system categorized as 
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abnormal, resulting in an immune response and tumor rejection (4). However, in 1957, Dr. 
Richmond Prehn and Dr. Joan Main published work that challenged this belief (4). They 
were able to show that each tumor differed from another in regards to its antigen 
expression (4). In their experiment, inbred mice were immunized against tumors induced 
by the chemical methylcholanthrene. These mice were protected against re-inoculation 
with the same tumor but not against inoculation with other tumors induced by 
methylcholanthrene in the same host, likely because each individual tumor led to different 
mutations and, in turn, antigens (4). At the same time, spontaneous tumors could not offer 
the same sort of protection, as each spontaneous tumor would have its own set of unique 
antigens (4).  
     The understanding that the immune system played a role in the regression of and 
protection against chemically-induced tumors led to questions about mechanisms by 
which this regression and protection occurred. The adaptive immune system is comprised 
of two distinct components: humoral immunity and cell-mediated immunity. Humoral 
immunity is regulated by B lymphocytes (B cells), while cell-mediated immunity involves 
the function of T lymphocytes (T cells) (5). B cells become the source of antibodies that 
circulate in the blood and bind to antigens to target them for processes such as 
phagocytosis (5). T cells work to recognize peptides presented by major histocompatibility 
complexes (MHC) I and II (5). Both are important aspects of the overall immune response, 
but the goal was to understand which of these pathways mediated tumor protection.  
     Work done by George and Eva Klein in 1960 (6) provided answers to this question. They 
conducted experiments where tumor cells were exposed separately to either serum or 
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lymph node cells from both untreated and pre-immunized mice to establish whether 
tumor protection stemmed from humoral or cell-mediated immunity, respectively. Their 
results showed that the tumor cells exposed to serum from the untreated and pre-
immunized mice and lymph node cells from the untreated mice showed similar and 
uninhibited patterns of tumor growth, whereas the tumor cells exposed to lymph node 
cells from pre-immunized mice showed inhibited tumor growth (6). To further validate this 
conclusion, a similar experiment was carried out in vivo, which also showed that lymph 
node cells from pre-immunized mice could confer protection against the tumor in another 
mouse when adoptively transferred.   
     These early experiments laid the foundation for understanding the mechanisms of 
tumor immunity and tumor specificity. Collectively, they showed that the immunization of 
mice with syngeneic tumors could lead to later resistance against these same tumors. 
Further, each tumor could bring about immunity against itself and no other tumor, 
regardless of the similarity in tumor type. It is from these canonical findings that the field 
of cancer immunology and immunotherapy has since grown.   
 
ANTIGENS AND NEOEPITOPES 
     Broadly, the term antigen refers to anything (proteins, glycoproteins, polysaccharides, 
etc.) that can be recognized by the adaptive immune system (5). Endogenous proteins get 
processed in the cytoplasm of a cell by the proteasome, which cuts the protein into smaller 
segments of 8-11 amino acids for class I (direct) presentation. These segments are the 
antigens that then get imported into the endoplasmic reticulum (ER) where they bind to 
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MHC class I. Segments that are longer than 8-11 amino acids upon ER import are trimmed 
by ERAP (5). The peptide-MHC complex then leaves the endoplasmic reticulum, is 
transported through the Golgi and then presented on the surface of all nucleated cells to 
allow for immune surveillance (5). Exogenous proteins are presented on the MHC class I of 
macrophages, dendritic cells, and certain other cells by cross-presentation (7). This latter 
type of processing is vital for naïve T cell priming and T cell activation.  
     CD8+ T cells are able to recognize presented antigens in the context of the peptide-MHC 
interaction through their T cell receptor (TCR). Each TCR has the ability to recognize only 
one peptide-MHC complex, though there is evidence of cross-reactivity (5). Under normal 
conditions, when non-mutated, self-antigens are presented, the immune system 
establishes that nothing is wrong and no action is taken. While tumors do contain 
mutations, they will also have normal proteins and, therefore, will present normal 
antigens. While Prehn and Main (1957) showed that each tumor can illicit protection only 
against itself due to a unique set of tumor-specific antigens, that is not to say that the role 
of shared tumor-associated antigens is entirely irrelevant (3).  
     There are cases in which differences in normal antigen presentation, through the 
process described above, can alert the immune system to the presence of cancerous cells. 
Tumor-associated antigens are aberrantly expressed self-antigens, meaning that while 
normal tissues do express these antigens, the degree of expression between the tumor 
and normal tissue significantly varies (8). Further, the discrepancy may be in that the tumor 
causes the expression of these normal antigens in tissues where they are not usually found 
(8). The immune system can pick up on such changes and mount the appropriate immune 
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response. It is the presence of “driver mutations”, which confer growth and survival 
advantages by affecting genes that promote cancer development, that can cause the 
immune system to overlook cancerous cells (9). For example, cancer cells may upregulate 
proteins that put the brakes on the immune response (9). In such cases, cancerous cells 
must be brought to the attention of the immune response by some other mechanism. 
     “Passenger mutations” are point mutations that cause changes in genes that do not 
cause cancer development (10). These mutations are different from tumor to tumor and 
even from individual to individual, in turn giving rise to tumor-specific epitopes through 
the process of antigen-presentation that normal cells undergo (11). These mutated 
antigens are termed neoepitopes. Further research showed that these mutant peptides 
could also serve as T cell epitopes in the same way that previously discovered antigens 
could (12, 13). Importantly, CD8+ T cells can distinguish these neo-epitopes as mutated 
and non-self (14). 
     Recognition of antigens and neoepitopes as self or non-self (“mutated” self), 
respectively, occurs in the lymph nodes, where antigen-presenting cells (APCs) such as 
dendritic cells and naïve T cells interact (5). When a naïve T cell encounters its cognate 
antigen or neo-epitope, the TCR will bind to the peptide-MHC complex, establishing the 
first signal needed for T cell activation. The second signal occurs when CD80 and CD86 on 
the APC binds to CD28 on the CD8+ T cell. The third and final signal for T cell activation 
occurs when the APCs or other cells produce inflammatory cytokines that assist in the 
priming and differentiation of the T cells.  
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     Activated T cells can then leave the lymph node to circulate and recognize their 
respective antigens or neoepitopes on other nucleated cells. Activated T cells that are 
specific to the cancer neoepitopes can then find and target cancer cells, thereby causing 
tumor regression. While ideally this alone would prevent tumor growth and metastasis, 
the immune system has mechanisms that can prevent targeted killing processes of CD8+ T 
cells from taking place. These mechanisms can become co-opted by the tumor for 
protection, as discussed in the next section. 
     Given the specificity of these neoepitopes, they are currently a prominent topic of 
research in regards to cancer immunology and immunotherapy. Through new 
bioinformatics and genomic sequencing techniques, the ability to predict neoepitopes for 
different cancers has greatly improved though there is still room for improvement (15). 
Predicted neoepitopes are important for individualized immunotherapy vaccines as they 
give the immune system exposure to neoepitopes specific to the host’s cancer (15).  
 
CTLA-4 AND PD-1  
     In order to prevent cases of autoimmunity, the immune system has established 
inhibitory mechanisms that will slow down the immune system. Normally, these 
mechanisms work in equilibrium with stimulatory mechanisms to maintain a state of 
homeostasis and well-being. However, in the case of cancer, inhibitory mechanisms can be 
inappropriately utilized. Two immune checkpoints that play a role in inhibitory mechanisms 
that are important specifically to cancer immunology are cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).  
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     CTLA-4 functions during both the priming and effector phases. Referring back to the 
three signals required for T cell activation, an interaction between CD80 and CD86 on the 
APC with CD28 on the T cell was required (i.e. signal 2). When this binding occurs, a 
proliferation of T cells, increased T cell survival, and T cell differentiation is seen (16). 
However, after signal 1 occurs with the TCR binding to the peptide-MHC complex, T cells 
also begin to express CTLA-4 (17). CTLA-4 competes with CD28 to bind CD80/86 on the APC 
(17). If signal 2 is not strong enough, CTLA-4 may be able to successfully outcompete CD28. 
This interaction prevents activation of these T cells.  
     If CD28 is not outcompeted during the priming phase, activated T cells leave the lymph 
node normally. During the effector phase, CTLA-4 can continue to be expressed and bind 
ligands if they are present in the target tissue. Should this binding occur, inhibitory signals 
are produced that counteract the stimulatory signals, resulting in non-functional T cells 
and thus putting the “brakes” on the immune system response. Further, T regulatory cells 
(Tregs) constitutively express CTLA-4 (18). Tregs, which are present in both the tumor 
microenvironment and lymph nodes can also contribute to the suppressed immunity by 
binding of their CTLA-4 to CD80/86 on APCs, thus reducing the available “signal 2” for T 
cell activity. In normal situations, this inhibition is essential to help to prevent 
autoimmunity, but in the case of cancer, the inhibition can allow the tumor to escape the 
immune response and continue to grow (18).  
     PD-1, like CTLA-4, causes inhibition of the immune response after interaction with one 
of its two ligands, PD-L1 or PD-L2 (19). This inhibition is achieved by the prevention of 
phosphorylation of key signaling intermediates in the T cell, which reduces activation (19). 
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PD-1 is first expressed on T cells after the TCR interacts with the peptide-MHC complex but 
gets downregulated during the beginning parts of the effector phase. In cases where T cells 
become exhausted due to constant and prolonged stimulation, as can happen in cases of 
inflammation or in the tumor microenvironment, PD-1 once more becomes upregulated 
(20). Exhausted T cells are dysfunctional, which means they cannot fight infections and 
tumors to the best of their ability, which directly results from PD-1’s ability to inhibit T cells 
and slow down the immune response (19).  
     While both CTLA-4 and PD-1 are important for normal functioning of the immune 
system, in regards to cancer they may be more detrimental than beneficial. Through their 
inhibitory mechanisms, they could counteract the effects of neoepitope vaccines. For this 
reason, experimental and clinical trials of immunotherapy vaccines are often paired with 
antibodies targeting these immune checkpoint molecules, which has been shown to lead 
to decreased tumor growth and improved survival (22, 23). With these treatment, a 
balance has to be achieved to ensure that the function of CTLA-4 and PD-1 in preventing 
autoimmunity is not compromised as a result. 
     By blocking CTLA-4, more T cells can be activated and can proliferate during the priming 
phase. During the effector phase, there may be less suppression of the T cell response by 
Tregs, allowing for a more robust immune response that could lead to tumor regression 
(23). Current clinical trials involve two versions of the human anti-CTLA-4 antibody: 
ipilimumab and tremelimumab, with ipilimumab being the first to show a survival benefit 
in and be FDA approved for patients with metastatic melanoma (24).  
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     PD-1 blockade allows T cells that were “turned off” or dysfunctional during the effector 
phase to once more become active, despite long or high levels of antigen exposure (25). 
Similarly to CTLA-4 blockade, this inhibition removes the breaks from the immune system, 
allowing it to more effectively fight off the tumor. Though clinical research with PD-1 
blockade is newer than that with CTLA-4 blockade, early results have shown much 
potential. In Phase I clinical trials of colon, lung, renal, lung cancers, and melanoma, some 
instances of tumor regression - partial and complete - were observed (26). There also 
appeared to be fewer immune-related toxicities from the PD-1 blockade than there were 
with the CTLA-4 blockade (26). Like ipilimumab, the PD-1 antibody, pembrolizumab, is FDA 
approved for treatment in patients with unresectable or metastatic solid tumors that have 
a specific biomarker (27). Tumors with the required biomarker are commonly found in 
colorectal, endometrial, and gastrointestinal cancer and are less commonly found in 
breast, prostate, bladder, and thyroid gland cancer (27).  
     Despite the general understanding of the mechanisms and purposes of CTLA-4 and PD-
1, there is still much to understand about how blockades of these immune checkpoints 
facilitate tumor regression. The fact that CTLA-4 is thought to function more in early tumor 
activation (priming) while PD-1 has a greater effect during the effector phase may make 
one treatment a better option over the other, and this may change from tumor to tumor. 
While clinical data is promising, a deeper understanding of the immunological changes that 
occur as a result of these two treatments will help guide future decisions in regards to 
immunotherapy.  
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PROJECT GOALS  
     The Srivastava lab has done a lot of work involving the creation and use of personalized 
neoepitopes for cancer therapy (28). This is done by taking the tumor of interest and 
sequencing it to identify tumor specific somatic mutations. Given these mutations, various 
bioinformatics techniques can be implemented to predict and synthesize neoepitopes 
specific to the tumor. These neoepitopes are then used in conjunction with a CTLA-4 
blockade in an attempt to illicit tumor regression in tumor bearing mice. 
     The lab has shown that BALB/cJ mice immunized with 11 computationally predicted 
neo-antigens and treated with a CTLA-4 antibody showed increased tumor rejection (29). 
However, work in the lab has also shown that there are neoepitopes that are not as 
effective in generating tumor rejection, even in conjunction with the CTLA-4 blockade. As 
part of a summer research project, I attempted to test these neoepitopes with a PD-1 
blockade instead to see if different results were seen. However, given the intrinsic ability 
of the PD-1 blockade to initiate tumor regression, little could be said about the synergistic 
impact various neoepitopes had on its function (data not shown).  
     The results from this experiment, led to the conclusion that it would first be beneficial 
to look at how CTLA-4 and PD-1 blockade treatments cause changes to the levels of 
immune cell populations throughout the body. In order to quantify these levels, different 
immune cell populations, both adaptive and innate, in the spleen, lymph node, blood, and 
tumor of mice were phenotyped. Specifically, the immune cell populations in naïve (non-
tumor bearing) young and old mice were taken as a baseline. From there, the effect of a 
tumor challenge and of the two treatment options was analyzed and compared to the 
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baseline levels. Hopefully, this understanding can provide insight into the actual 
mechanism of action for each treatment and answers as to in which circumstances one 
treatment might be a better option than the other.  
 
MATERIALS/METHODS 
MICE 
     Female BALB/cJ and C57BL/6 (BL/6) mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME) at 6-8 weeks old. The mice were housed and cared for in the virus-free 
mouse facilities at UConn Health. Use of these mice was approved and monitored by the 
Institutional Animal Care and Use Committee. Old mice that were used for the age 
comparison studies were purchased at 6-8 weeks old and housed in these facilities until 
reaching 8-12 months of age.   
 
TUMOR CELL LINE 
     The tumor cell line used for these experiments was Meth A, a fibrosarcoma induced by 
methylcholanthrene in a female BALB/cJ mouse. Meth A ascites was used for passage and 
challenge in BALB/cJ mice. The MethA used in these experiments was obtained from a 
frozen stock in the lab.  
 
TUMOR CHALLENGE 
     The day prior to tumor challenge, BALB/cJ mice were shaved. On the day of the tumor 
challenge, the mice were inoculated with 95,000 live Meth A ascites cells. The cells were 
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intradermally injected on the lower right flank of the mice. Every three days following the 
tumor challenge, the mice in the treatment groups were injected with a dose of either 60 
g/mouse monoclonal anti-CTLA-4 antibody or 200 g/mouse monoclonal anti-PD-1 
antibody, which were purchased from BioXCell (West Lebanon, NH). Measurements of the 
tumor diameters were taken twice a week with calipers. Mice were sacrificed either at 12 
days (early tumor) or 21 days (late tumor) post tumor challenge. 
  
TISSUE HARVEST 
     Blood was obtained from the mice through a heart-stick procedure. Mice were 
anesthetized with a ketamine/xylazine mixture and blood was drawn into a needle 
following heart puncture. After 800L-1mL of blood was obtained, the mice were sacrificed 
and the inguinal lymph nodes, spleen, and tumor (if applicable) were removed. For tumor 
bearing mice, only the draining lymph node was collected. 
 
FLOW CYTOMETRY ACQUISITION 
     Immune cell populations of the harvested tissues were analyzed by flow cytometry 
through use of a MACSQuant®. Relevant tissues were prepared into single-cell suspensions 
to allow for processing by flow cytometry. Cells were plated in a 96-well plate at a 
concentration of ~2 * 106 cells/well. Tissue samples from each respective mouse were 
plated in triplicate and stained with an antibody mixture corresponding to one of three 
panels (NK/T-cell/B-cell, dendritic cell, macrophage/monocyte).  
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     For the lymphocyte/NK panel, cells were stained for CD8 (VioBlue, clone 53-6.7; 
Miltenyi), B220 (Brilliant Violet 510, clone RA3-6B2; Biolegend), CD4 (FITC, clone GK1.5; 
eBioscience), CD3 (PE, clone 145-2C11; eBioscience), FoxP3 (PerCP-Cy5.5, clone FJK-16s; 
eBioscience), CD19 (PE-Cy7, clone SJ25-C1; eBioscience), and CD49b (APC, clone DX5; 
Biolegend). 
     For the dendritic cell panel, cells were stained with F4/80 (Pacific Blue, clone BM8; 
Biolegend), CD8 (BV510, clone 53-6.7; BD), CD103 (FITC, clone 2E7; Biolegend), CD80 (PE, 
clone 16-10A1; BD), CD86 (PE, clone B7-2; BD), CD11c (PerCP-Cy5.5, clone HL3; BD), CD11b 
(PE-Cy7, clone M1/70; Biolegend), and MHCII (APC, clone M5/114.15.2; eBioscience). 
    For the macrophage/monocyte panel, cells were stained with F4/80 (Pacific Blue, clone 
BM8; Biolegend), CD115 (BV510, clone T38-320; BD), CD68 (FITC, clone FA-11; 
eBioscience); CD64 (PE, clone X54-5/7.1; eBioscience), Ly-6C (PerCP-Cy5.5, clone HK1.4; 
eBioscience), CD11b (PE-Cy7, clone M1/70; Biolegend), and GR-1 (Alexa Fluor 700, clone 
RB6-8C5; Biolegend).  
     Compensation of the machine was accomplished using spleen samples stained with 
antibodies in the same colors as used for each panel. The compensation control samples 
were run prior to data acquisition so that the MACSQuant® could adjust for overlap 
between the colors used to stain the actual samples.  
 
FLOW CYTOMETRY ANALYSIS 
     Cell were gated first based on size (forward scatter) and granularity (side scatter). The 
population of single cells was then selected for by plotting forward scatter height against 
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forward scatter area. A gate was then placed around the population of live cells. From that 
point on each panel was individually analyzed dependent on the immune cell markers 
stained for. Results were analyzed using the FlowJo 10.3 software.  
 
STATISTICAL ANALYSIS 
     Statistical significance was determined using a paired Student t-test (two tailed). The 
difference between two subsets of data was considered statistically significant if the 
Student t-test gave a significance level P (P value) less than 0.05 (*). The difference was 
considered very significant if the Student t-test gave a P value less than 0.01 (**). The 
difference was considered extremely significant if the Student t-test gave a P value less 
than 0.001 (***).  
 
RESULTS 
FLOW CYTOMETRY ANALYSIS OF LYMPHOCYTE POPULATIONS      
     Of the three panels created for these sets of experiments, the lymphocyte panel was of 
the greatest interest, as those cells are key players in current cancer immunotherapy 
research. Lymphocytes consist of T cells, B cells, and NK cells. The panel was generated 
with the aim of separating out various subtypes of these three cell types.  
     Prior to gating for specific cell types, a gate was formed around the population of 
interest by plotting size (forward scatter) against granularity (side scatter). From this target 
population, only single cells were analyzed. These were identified by plotting forward 
scatter height against forward scatter area. During the staining process, the samples were 
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marked with a live-dead stain.  This allowed for selection of live cells from the single cell 
population. These preliminary gating steps were consistent across each of the three panels 
and were always done prior to more detailed cell analysis (Figure 1).   
     After selecting for live cells, T cells and relevant subsets were identified (Figure 2a). All 
T cell populations were identified by the presence of the CD3 surface marker. From this 
general T cell population, the subsets of T helper cells (CD3+CD4+) and cytotoxic T cells 
(CD3+CD8+) were identified through CD4 and CD8 antibody staining, respectively. 
Intracellular staining with the FoxP3 allowed for identification of Tregs (CD3+CD4+FoxP3+).  
     B cells were identified through CD19 and CD45 (B220) antibody staining (Figure 2b). 
CD19 is a B cell specific protein that appears early on in B cell development and remains 
throughout the maturation process, though its levels do decrease as activated B cells 
become plasma cells. CD45 is present throughout the entire maturation timeline as well. 
Therefore, B cells, for the purposes of this experiment, were identified as CD3-
CD19+CD45+.  
     Lastly, isolation of NK cells was possible through CD49b antibody staining (Figure 2c). To 
ensure that natural killer T cells (NKT) were not included in this population, only CD3-
CD49b+ NK cells were selected. When including NKT cells, the CD3+CD49b+ population 
was taken.  
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Figure 1: General Gating Strategy  
General work flow applied to each of the three panels used for data analysis. From left to right: selection of 
cells of interest, selection of single cell population, selection of live cell population.  
 
 
Figure 2: Lymphocyte Gating Strategies 
(a) Gating strategy for identifying subsets of T cells. From left to right: separation of CD3+ and CD3- cells, 
identification of CD4+ and CD8+ T cells off of CD3+ gate, identification of Tregs off of CD4+ gate. (b) Gating 
strategy for B cell identification off of CD3- gate. (c) Gating strategy for NK cell identification off of CD3- gate.  
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FLOW CYTOMETRY ANALYSIS OF DENDRITIC CELL POPULATIONS      
     Initial gating steps were done as described in the “Flow Cytometry Analysis of Dendritic 
Cell Populations” section (Figure 1). F4/80 was included as an exclusion marker in this 
panel, as it is known to be a macrophage marker. Therefore, F4/80- cells were gated for 
off of the live cell population to ensure that macrophages were not included in analysis of 
this panel. Further analysis of this data is still ongoing and will not be discussed in this 
thesis.   
 
FLOW CYTOMETRY ANALYSIS OF MONOCYTE POPULATIONS      
     Initial gating steps were done as described in the “Flow Cytometry Analysis of Dendritic 
Cell Populations” section (Figure 1). To isolate the general macrophage population, the 
F4/80+ cells were selected for. Further analysis of this data is still ongoing and will not be 
discussed in this thesis.  
 
VARIATION BETWEEN STRAINS OF MICE 
     The Srivastava lab works almost entirely with either BALB/cJ or BL/6 mice. It is known 
that BALB/cJ mice are more likely to produce a Th2 immune response, whereas BL/6 mice 
tend to produce Th1 immune responses (30). These two immune responses differ in 
regards to the cytokines that are produced, though a balance between the two is 
important for effectively fighting off a variety of diseases (31, 32, 33). A typical Th1 
responses involves high levels of interferon- (IFN-) and low levels of interleukin (IL)-4 
(30). Th2 responses, on the other hand, produce low levels of IFN- and high levels of IL-4 
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(30). These seemingly small differences can have a large impact on how each individual 
strain responds to a given therapy.  
     Along with this inter-strain variation, intra-strain variation has also been observed. A 
2016 study compared how BL/6 mice sourced from Taconic Biosciences, The Jackson Labs, 
NCI/Charles River Labs, and Harlan/Envigo reacted to infection with Plasmodium yoeilli 
(34). The same experiment was also conducted in BALB/cJ mice. The results showed that 
mice from Taconic Biosciences and The Jackson Labs were resistant to the infection, 
showing no signs of morbidity or mortality (34). However, the NCI/Charles River Labs and 
Harlan/Envigo mice presented with weight loss, mortality, and parasitemia (34).  
     Sivan et al. also looked at this intra-strain variation, by observing melanoma growth in 
BL/6 mice from either Taconic Biosciences or The Jackson Labs (35). They found that the 
mice from Taconic Biosciences had more aggressive melanoma growth, while The Jackson 
Lab mice had more intratumoral CD8+ cells (35). These two studies show that sourcing 
seemingly identical strains from different laboratories can have a significant impact on 
study outcomes.  
     Given this knowledge that BALB/cJ and BL/6 mice have inherent differences in their 
immunological makeup both between and within strains, it seemed important to have a 
baseline understanding of the mice frequently utilized in the lab. Therefore, before looking 
further into the effects of treatments on immune cell levels in BALB/cJ mice, immune cell 
populations were compared across the blood, lymph node, and spleen of these two strains 
in both young and old naïve mice. Quantification of these populations is shown in 
Supplemental Tables 1, 2, 3, and 4. 
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     Comparison of T cell levels (CD3+) between young naïve BALB/cJ and BL/6 mice showed 
statistically different levels in the blood and lymph node (Figure 3a). While BALB/cJ mice 
appeared to have higher levels in the lymph node, BL/6 mice showed a higher blood T cell 
count. To get a better understanding of how the different T cell populations varied 
between the two strains, comparisons of the CD4+ and CD8+ populations were also 
conducted. BL/6 mice were found to have significantly more CD8+ T cells as a percentage 
of total CD3+ across each tissues that was analyzed (Figure 3b). In contrast, there were 
significantly more CD4+ cells in the lymph node and spleen of BALB/cJ mice (Figure 3c).  
     Within the CD4+ population, Treg levels (CD4+FoxP3+) were not significantly different 
in any of the three tissues when comparing the two strains (Figure 3d). Though the results 
for Tregs were not of statistical significance in this experiment, the data showed that 
BALB/cJ Treg counts were trending higher in the blood and spleen. This finding supports 
previous literature in the field that has shown that BALB/cJ mice have more Tregs than 
BL/6 mice (36).  
     While T cells demonstrated significant variation in regards to their distribution between 
BALB/cJ and BL/6 mice, much less variation was observed when looking at B cells. These 
levels were not significantly different across the two strains when looking at the blood and 
spleen, though B cell levels were significantly higher in the BALB/cJ lymph nodes (Figure 
3e). At first look, there seems to be a difference in the NK cell levels for each tissue between 
both types of mice. However, statistical analysis showed that the difference in NK cells was 
only statistically significant in regards to the spleen, with BL/6 mice showing higher levels 
(Figure 3f). 
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Subsets of immune cells were compared across naïve young BALB/cJ and BL/6 mice in the blood, lymph node, 
and spleen. Statistical significance was shown as follows: P value < 0.05 (*), P value < 0.01 (**), P value < 
0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) Comparison of CD4+ cells. (d) 
Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells.  
Figure 3: Comparison of Immune Cell Levels in Naïve Young BALB/cJ and BL/6 Mice 
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     After observing significant differences in the immune cell populations of young naïve 
BALB/cJ and BL/6 mice, the question arose as to whether these differences persisted as 
the mice aged. Therefore, a similar comparison process was done between immune cells 
levels in the blood, lymph node, and spleen of older (8-12 months) naïve BALB/cJ and BL/6 
mice.  
     The initial variation in T cell levels that was seen between naïve young BALB/cJ and BL/6 
mice seemed much less prominent in the older mice (Figure 4a). While BALB/cJ had a 
significantly higher amount of CD3+ cells in the lymph node, the levels between the older 
mice was insignificant. BL/6 mice did continue to have significantly more CD3+ cells in the 
blood as they aged. Of interest was the result that older BL/6 mice had more CD3+ cells in 
the spleen than older BALB/cJ mice. In the younger mice, this pattern was reversed. 
However, the difference was not great enough to be significant in either case.  
     Despite less variation in overall T cell levels, differences in the amount of CD4+ and CD8+ 
cells increased (Figures 4b and 4c, respectively). As with the younger mice, older BALB/cJ 
had higher CD4+ cell levels in each of the three tissues analyzed. While the difference in 
blood CD4+ cell levels had not been significant in younger mice, it became so in the older 
population. Comparisons of CD8+ cell levels had shown significantly higher levels in the 
blood, lymph node, and spleen of younger BL/6 mice, and these levels grew over time while 
BALB/cJ levels appeared to remain constant. Further, Treg levels had not been significantly 
different between the two strains when looking at younger mice. It was only in the older 
mice that the differences in the blood and spleen became significant with higher levels in 
the BALB/cJ mice (Figure 4d).   
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Figure 4: Comparison of Immune Cell Levels in Naïve Old BALB/cJ and BL/6 Mice 
Subsets of immune cells were compared across naïve old BALB/cJ and BL/6 mice in the blood, lymph node, 
and spleen. Statistical significance was shown as follows: P value < 0.05 (*), P value < 0.01 (**), P value < 
0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) Comparison of CD4+ cells. (d) 
Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells. 
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     There was also a shift in results when looking at the B cell populations of these three 
tissues (Figure 4e). In younger mice, BALB/cJ mice had shown significantly higher levels in 
the lymph node. While levels were still higher in older BALB/cJ mice than in older BL/6 
mice, the difference was no longer significant. However, older BALB/cJ had an overall 
increase in splenic B cells, making the difference between them and the older BL/6 spleen 
B cell levels significant.  
     The comparison of NK cells in older also differed slightly from the younger mice, with 
BALB/cJ now showing significantly more NK cells in the lymph node than the BL/6 mice did 
(Figure 4f). In the younger mice, BL/6 mice had significantly more NK cells in the spleen, 
but this pattern changed in the older mice, with BABL/cJ mice showing significantly more 
cells (Figure 4f).  
 
EFFECT OF AGE ON IMMUNE CELL POPULATIONS 
     It is well known that aging can have detrimental effects on the immune system due to 
circumstances such as reduced B and T cell production and sub-optimal functioning of 
mature lymphocytes in secondary lymphoid tissues (37). These characteristics make it 
difficult for elderly people to have immune responses as strong and robust as younger 
people, as they are less likely to efficiently respond to novel antigen exposure (37). Further, 
it has been shown that as mice age, their number of lymphoid biased hematopoietic stem 
cells (HSC) declines. (38). The few remaining lymphoid-based HSCs are also susceptible to 
deficiencies that inhibit their self-renewal population, resulting in even fewer cells of this 
population (39).  
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     Along with reduced lymphocyte function, aging mice have impaired Th1 and Th2 
cytokine production (40). As stated previously, BALB/cJ and BL/6 mice rely on Th2 and Th1 
immune responses, respectively. Cytokine production is necessary for effective 
implementation of this response. Other studies have also shown that aging mice 
downregulate MHC class II on their APCs, which results in decreased presentation of tumor 
antigen to naïve CD4+ T cells (41). This, in combination with normal presentation of tumor 
antigen to CD8+ T cells on MHC class I, can lead to tolerization and not activation of tumor 
antigen-specific CD8+ cells (41).  
     Given the changes in the immune system associated with aging, it seemed plausible that 
the efficacy of immunotherapy could vary in younger mice models versus older mice 
models. To establish a baseline understanding of how the immunological makeup of each 
strain changed from 6-8 weeks to 8-12 months, an intra-strain comparison was conducted 
on the blood, lymph node, and spleen immune cell levels of young and old BALB/cJ and 
BL/6 mice. Comparisons were done using data from Supplemental Tables 1, 2, 3, and 4.   
     BALB/cJ mice showed changes in their T cell populations as they aged. Younger mice 
had significantly more overall T cells in the lymph node and the spleen along with 
significantly higher CD4+ cells in the lymph node (Figure 5a, 5c). On the other hand, CD8+ 
and Treg levels were higher in older BALB/cJ mice, with CD8+ levels being significantly 
higher in the blood and lymph node and Treg levels being significantly higher in the lymph 
node and spleen (Figure 5b, 5d). There was no significant change difference in B cell 
distribution, though NK cells significantly increased in the lymph nodes and spleen of the 
older mice (Figure 5e, 5f).  
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Figure 5: Comparison of Immune Cell Levels in Naïve Young and Old BALB/cJ Mice 
Subsets of immune cells were compared across naïve young and old BALB/cJ mice in the blood, lymph node, 
and spleen. Statistical significance was shown as follows: P value < 0.05 (*), P value < 0.01 (**), P value < 
0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) Comparison of CD4+ cells. (d) 
Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells. 
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     Even less variation was observed between young and old BL/6 mice. No significant 
differences in CD3+ populations were seen in any of the three tissues (Figure 6a). However, 
there was some variation when looking at CD8+ cells. Young BL/6 mice had significantly 
more CD8+ cells in the blood while older BL/6 mice had significantly higher levels in the 
lymph nodes (Figure 6b). As with the CD3+ cells, no significant variation was seen in the 
CD4+ populations of the blood, lymph node, or spleen (Figure 6c). Analysis of Treg levels 
did show significantly higher levels in the blood of young BL/6 mice and the spleen of old 
BL/6 mice (Figure 6d). Like with the BALB/cJ mice, there was no significant difference in B 
cell levels (Figure 6e). There were, however, significantly more NK cells in the spleen of 
younger BL/6 mice (Figure 6f).  
     The findings from both BALB/cJ and BL/6 mice that showed no significant difference in 
B cell levels is in line with previous literature in the field. While peripheral B cells have been 
shown to decrease in humans as they age, the levels in older mice appear to be normal 
(42). Rather, what tends to occur is that there is a decreased output of naïve B cells, which 
results in expansion of antigen-experienced B cell clones (43). However, this would not be 
useful to individuals that acquired cancer at later stages in life, as their memory B cells 
would not be specific to the tumor antigens.  
     BL/6 data for NK cells is also supported by previous studies that showed reduced 
percentages of NK cells in the spleen and blood of aged mice and stable percentages of NK 
cells in the lymph nodes (44, 45).  There is no prior literature on the variation in NK cells 
levels of aging BALB/cJ mice.   
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Figure 6: Comparison of Immune Cell Levels in Naïve Young and Old BL/6 Mice 
Subsets of immune cells were compared across naïve young and old BL/6 mice in the blood, lymph node, and 
spleen. Statistical significance was shown as follows: P value < 0.05 (*), P value < 0.01 (**), P value < 0.001 
(***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) Comparison of CD4+ cells. (d) 
Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells. 
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EFFECT OF TUMOR BURDEN ON IMMUNE CELL POPULATIONS 
     Following collection of the baseline immune cell levels in naïve mice, the effect of 
inoculating mice with tumors needed to be determined. Initially, naïve mice were 
compared with early tumor-bearing mice (12 days post-tumor challenge) to gauge the 
impact that the presence of a tumor would have on the subject. Further analysis was done 
between early tumor-bearing mice and late tumor-bearing mice (21 days post-tumor 
challenge). Since previous work in the lab has shown that the majority of untreated mice 
did not show tumor regression, it seemed interesting to analyze how immune cell levels 
changed throughout the course of tumor growth (unpublished data). The goal was to gain 
some understanding of how different immune cell populations changed in response to 
initial and prolonged tumor growth, as that could provide insight into future treatment 
options and timelines. Data used for this analysis is shown in Supplemental Tables 5 and 6. 
     Compared to naïve mice, early tumor-bearing mice had significantly lower levels of 
CD3+ T cells in their lymph nodes and spleen (Figure 7a). While they also showed lower 
CD8+ levels in the blood and spleen, these differences were not found to be significant. 
They did, however, have significantly more CD8+ cells in the lymph node (Figure 7b). Early 
tumor-bearing mice also showed decreases in CD4+ cell levels in the spleen and lymph 
node, though the difference was only significant in the latter (Figure 7c). Changes in Treg 
levels were not found to be significant in any of the three tissues (Figure 7d). The 
percentage of B cells decreased in all three tissues but was only significant in regards to 
the lymph nodes (Figure 7e). NK cells showed a great deal of variation, with significant 
increases in blood and spleen levels of early tumor-bearing mice (Figure 7f).   
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Figure 7: Comparison of Immune Cell Levels in Naïve Young and Early Tumor Bearing BALB/cJ 
Mice 
Subsets of immune cells were compared across naïve young and early tumor bearing BALB/cJ mice in the 
blood, lymph node, and spleen. Statistical significance was shown as follows: P value < 0.05 (*), P value < 
0.01 (**), P value < 0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) Comparison 
of CD4+ cells. (d) Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells. 
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     When comparing early tumor-bearing and late tumor-bearing mice, it was found that 
CD3+ levels increased in the latter group in the blood, lymph node, spleen, and tumor. 
Despite these overall increases, the only significant difference occurred in the blood and 
spleen (Figure 8a). With CD8+ T cells, decreases were seen in the late tumor-bearing mice 
as compared to the early tumor-bearing mice when looking at the blood, lymph node, and 
spleen, with only the spleen showing a significant decrease (Figure 8b). Within the tumor 
microenvironment, CD8+ levels in the late tumor-bearing mice were insignificantly higher. 
CD4+ T cell levels in late tumor-bearing mice were decreased in each of the tissues relative 
to early tumor-bearing mice but were only significantly different in the tumor 
microenvironment (Figure 8c). As with the comparison between naïve and early tumor-
bearing mice, there were no significant differences in Treg levels between early and late 
tumor-bearing mice in the blood, spleen, lymph node, or tumor microenvironment (Figure 
8d).  
     B cell levels in the blood, lymph node, and spleen of late tumor-bearing mice decreased 
with respect to early tumor-bearing mice. The decrease was only significant in the spleen. 
B cell levels within the tumor microenvironment stayed relatively stable (Figure 8e). NK 
cells showed the greatest amount of variation between the two tumor-challenged groups. 
Cell levels decreased in late tumor-bearing mice in each of the four tissues that were 
analyzed. Of these four, the reduction in NK cell level was found to be significant in three: 
the blood, spleen, and tumor microenvironment (Figure 8f). This result supports previously 
published data, which demonstrated that tumor growth had a detrimental impact on 
functional maturation of NK cells during development (46-48).   
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Subsets of immune cells were compared across early and late tumor bearing BALB/cJ mice in the blood, 
lymph node, spleen, and tumor. Statistical significance was shown as follows: P value < 0.05 (*), P value < 
0.01 (**), P value < 0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) Comparison 
of CD4+ cells. (d) Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells. 
Figure 8: Comparison of Immune Cell Levels in Early and Late Tumor Bearing BALB/cJ Mice 
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EFFECT OF IMMUNOTHERAPY ON IMMUNE CELL POPULATIONS 
     Studies previously done in the Srivastava lab have shown that administration of either 
anti-CTLA4 or anti-PD1 to tumor bearing mice has an effect on the course of tumor 
development and growth (unpublished data). These checkpoint blockade treatments are 
provided in combination with one of many predicted neoepitopes, in hopes of stimulating 
and prolonging the immune response against the tumor. However, the treatments do not 
have the same efficacy for each neoepitope that they are paired with (unpublished data). 
Further, in some cases, the two treatments have been shown to have different effects 
when used with the same neoepitope (unpublished data). To begin to get a better idea of 
why one therapy worked better than the other in some instances, the way in which each 
treatment affected the distribution of immune cells in the body was analyzed. Anti-CTLA4 
and anti-PD1 data are shown in Supplemental Tables 7 and 8, respectively. 
     Comparison between tumor-bearing (untreated) and anti-CTLA4 treated revealed that 
CD3+ cell levels were fairly stable across the two groups, though untreated mice did have 
significantly more CD3+ cells in the blood (Figure 9a). Despite the general lack of variation 
in CD3+ cells, much more variation was seen in the amount of various T cell subsets. CD8+ 
levels were significantly lower in the lymph nodes of treated mice but were found to 
significantly increase in the tumor microenvironment of these mice (Figure 9d). Anti-CTLA4 
treated mice showed significant increases in CD4+ levels in the spleen in the blood, though 
these levels significantly decreased in the tumor microenvironment following treatment 
(Figure 9c). Further, Tregs were significantly more present in the lymph nodes and spleen 
of mice that received the anti-CTLA4 treatment (Figure 4d).  
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Figure 9: Comparison of Immune Cell Levels in Tumor Bearing and anti-CTLA4 Treated 
BALB/cJ Mice 
Subsets of immune cells were compared across tumor bearing and anti-CTLA4 treated BALB/cJ mice in the 
blood, lymph node, spleen, and tumor. Statistical significance was shown as follows: P value < 0.05 (*), P 
value < 0.01 (**), P value < 0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) 
Comparison of CD4+ cells. (d) Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells.  
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     B cell and NK cell populations showed little to no variation between the untreated and 
treated groups. Significantly more B cells were present in the blood of anti-CTLA4 treated 
mice, but levels across the other tissues were relatively similar (Figure 9e). Though NK cell 
levels seemed to increase in each of the tissues from the treated mice as compared to the 
untreated mice, none of the increases were found to be significant (Figure 9f).  
     When looking at tumor-bearing and anti-PD1 treated mice, there were fewer significant 
changes in immune cell populations than seen in anti-CTLA4 treated mice. General T cell 
levels (CD3+ cells) were significantly lower in the blood of treated mice, while CD3+ levels 
were significantly higher in spleens of the same mice (Figure 10a). There were no 
significant changes in the levels of CD4+ cells and Tregs (Figure 10b, 10c). Despite the lack 
of significance, there was a trend of increasing Treg levels in each of the four tissues 
analyzed. CD4+ levels, on the other hand, remained relatively stable, though there was an 
insignificant decrease in the percentage of CD4+ cells in the tumors of treated mice. Unlike 
CD4+ cells and Tregs, some significant variation was seen in CD8+ cell levels (Figure 10d). 
Significantly many more CD8+ T cells were found in the blood of the mice given anti-PD1. 
CD8+ cell levels were significantly lower in the lymph nodes of these mice relative to the 
untreated tumor-bearing mice.  
     There did not appear to be any general trends in regards to B cells and NK cells. There 
were decreases in levels of these cells in some tissues and increases in others. Of all these 
changes, the decrease in B cells in the spleens of treated mice relative to untreated mice 
was the only one that was of significance (Figure 10e).   
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Figure 10: Comparison of Immune Cell Levels in Tumor Bearing and anti-PD1 Treated BALB/cJ 
Mice 
Subsets of immune cells were compared across tumor bearing and anti-PD1 treated BALB/cJ mice in the 
blood, lymph node, spleen, and tumor. Statistical significance was shown as follows: P value < 0.05 (*), P 
value < 0.01 (**), P value < 0.001 (***) (a) Comparison of CD3+ cells. (b) Comparison of CD8+ cells. (c) 
Comparison of CD4+ cells. (d) Comparison of Tregs. (e) Comparison of B cells. (f) Comparison of NK cells. 
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DISCUSSION 
     The data shown in this thesis demonstrates that many factors can have an impact on 
the immunological makeup of a mouse, including, but not limited to: strain, age, tumor 
burden, and treatment. This information can be helpful in guiding areas of future research 
and sheds light on the potential mechanisms of action that immune checkpoint blockade 
therapies such as anti-CTLA4 and anti-PD1 utilize. From the data in the results section, the 
following takeaway points can be highlighted.  
     There are significant differences in the immune cell populations of BALB/cJ and BL/6 
mice, and these differences persist and even increase throughout the lifetime of these 
strains. By 6-8 weeks, BALB/cJ characteristically had more CD4+ and less CD8+ T cells in 
each of the secondary lymphoid tissues than BL/6 mice of the same age. These differences 
were still present at 8-12 months and became much more significant. By this age, the 
higher levels of Tregs in the blood and spleen of BALB/cJ mice were also significant. Though 
young BL/6 mice had significantly more spleen NK cells than young BALB/cJ mice, by 8-12 
months, BALB/cJ mice had significantly more of these cells than BL/6 mice. This data 
implies that there is variation in the way the immune systems of these two strains 
functions. Therefore, identical therapies may result in different effects.  
     Along with this inter-strain discrepancy, there is also variation within the strains when 
comparing 6-8 week old mice and 8-12 month old mice. As previously mentioned, aging 
can affect the amount of certain immune cells that are present, while also having overall 
detrimental effects to the immune system. As expected, older BALB/cJ mice showed 
significantly less CD3+ cells in the lymph node and spleen, as well as significantly less CD4+ 
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cells in the lymph node. In contrast, CD8+ and Treg levels rose as BALB/cJ mice aged, with 
the difference being significant in the blood and lymph node for CD8+ cells and in the 
lymph node and spleen for Tregs. Older BL/6 mice also had significantly higher Treg levels 
in the spleen. The increase in amount of Tregs can be seen as evidence for how older mice 
may have less robust immune responses.  
     Results showing that tumor-bearing BALB/cJ mice had significantly lower levels of CD3+ 
cells in the spleen and CD3+ cells, CD4+ cells, and B cells in the lymph nodes exemplifies 
how cancer can affect the immune system. It is possible that lower levels of these cells are 
seen in the tissues analyzed because they migrated to the tumor microenvironment. 
However, the duration of tumor-bearing can also have an impact on these numbers. In 
general, it appeared that mice who had tumors for 21 days had less CD4+ cells, CD8+ cells, 
Tregs, B cells, and NK cells in the blood, lymph node, spleen, and tumor microenvironment 
relative to early tumor-bearing mice. Though not all changes were significant, the pattern 
of decreasing cell levels showed how, over time, untreated cancer has the ability to 
downregulate and escape the immune system.  
      The effect of tumor burden on BALB/cJ mice provided interesting data, which led to the 
question of how checkpoint blockade therapy might be able to counteract these effects. 
While the comparison of early and late tumor-bearing mice revealed decreases in the 
majority of immune cells studied, BALB/cJ mice that were treated with anti-CTLA4 showed 
different results. In regards to CD4+ cells, CD8+ cells, Tregs, B cells, and NK cells, there 
seemed to be an overall increase in cell numbers in the anti-CTLA4 treated mice. As an 
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exception, there were fewer Tregs in the tumor microenvironment, which may explain why 
anti-CTLA4 treated mice are better able to reject tumors than untreated mice. 
     The lack of variation in immune cell levels between untreated and anti-PD1 treated mice 
seems to support what is already known about the mechanism of action of anti-PD1. As 
previously described, anti-PD1 is not thought to function until the effector phase. In 
contrast, anti-CTLA4 begins working as early as the priming phase. Therefore, it is 
understandable that the effects of anti-PD1 may not have taken place in early tumor-
bearing mice.  
     Moving forward, it would be beneficial to look more closely at subsets of cells that were 
not included in this analysis and to re-evaluate some of the markers that were utilized. By 
choosing to look at more specific cell types, changes in the immunological makeup of these 
mice will be clearer. Further, as B cells mature, they display a variety of markers. While the 
two that were chosen are consistently present throughout these stages, it would be 
interesting to include more specific markers so that B cells at different stages in the 
maturation process could be isolated. In regards to the markers of choice, with NK cells, 
the marker utilized was CD49b. However, further literature review showed that NK1.1 is a 
more reliable marker in BL/6 mice. Making this change would allow for more accurate data.  
     Overall, the results from the experiments done as a part of this thesis have provided a 
lot of insight on how the immune system changes under varying conditions. This work will 
allow for future experiments that work to better understand the effects and mechanisms 
of action of different therapeutics that are being used in clinical trials today. 
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